Research Paper Volume 13, Issue 19 pp 23004—23019

lncRNA MEG3 aggravated neuropathic pain and astrocyte overaction through mediating miR-130a-5p/CXCL12/CXCR4 axis

MEG3 targeted miR-130-a-5p. (A) Binding locations between MEG3 and miR-130a-5p were predicted using the starbase v2.0 database. (B) The target association between MEG3 and miR-130a-5p in astrocytes was clarified by the dual-luciferase reporter assay. (C) RIP was implemented to monitor the binding relationship between MEG3 and miR-130a-5p in astrocytes. NSP>0.05, ***PD) The miR-130a-5p expression in astrocytes after up-regulation or down-regulation of MEG3 was gauged by RT-qPCR. (E) WB was conducted to test the expression of CXCL12, CXCR4, Rac1 and NF-κB in astrocytes after up-regulating or down-regulating MEG3. Data were expressed as mean±SD. n=3. **PPPP

Figure 5. MEG3 targeted miR-130-a-5p. (A) Binding locations between MEG3 and miR-130a-5p were predicted using the starbase v2.0 database. (B) The target association between MEG3 and miR-130a-5p in astrocytes was clarified by the dual-luciferase reporter assay. (C) RIP was implemented to monitor the binding relationship between MEG3 and miR-130a-5p in astrocytes. NSP>0.05, ***P<0.001(vs. miR-NC group). (D) The miR-130a-5p expression in astrocytes after up-regulation or down-regulation of MEG3 was gauged by RT-qPCR. (E) WB was conducted to test the expression of CXCL12, CXCR4, Rac1 and NF-κB in astrocytes after up-regulating or down-regulating MEG3. Data were expressed as mean±SD. n=3. **P<0.01, ***P<0.001 (vs. Vector group). &P<0.05, &&P<0.01 (vs. sh-NC group).